Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

by Ledermann, Jonathan A , Mądry, Radosław , Vergote, Ignace , Agarwal, Shefali , Buscema, Joseph , Dørum, Anne , Christensen, René D , Follana, Philippe , Oza, Amit M , Redondo, Andrés , Fabbro, Michel , Berek, Jonathan S , Marth, Christian , Benigno, Benedict , Lorusso, Domenica , Herrstedt, Jørn , Balser, John P , Tinker, Anna V , Gilbert, Lucy , Monk, Bradley J , González-Martín, Antonio , Matulonis, Ursula A , Rosenberg, Per , Ben-Baruch, Noa E , Mahner, Sven , Mirza, Mansoor R , du Bois, Andreas , Rimel, Bobbie J

in Adenosine / Adolescent / Adult / Aged / Aged, 80 and over / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Bone marrow / Bone Marrow - drug effects / Breast cancer / Cancer therapies / Clinical trials / Disease-Free Survival / Double-Blind Method / Drug therapy / Female / Genes, BRCA1 / Germ-Line Mutation / Health risk assessment / Homologous Recombination / Human health sciences / Humans / Indazoles - adverse effects / Indazoles - therapeutic use / Inhibitor drugs / Kaplan-Meier Estimate / Maintenance Chemotherapy / Middle Aged / Mutation / Médecine de la reproduction (Gynécologie, andrologie, obstétrique) / Neoplasm Staging / Neutropenia / Ovarian cancer / Ovarian Neoplasms - drug therapy / Ovarian Neoplasms - genetics / Patients / Piperidines - adverse effects / Piperidines - therapeutic use / Platinum / Platinum Compounds - therapeutic use / Poly(ADP-ribose) polymerase / Reproductive medicine (gynecology, andrology, obstetrics) / Ribose / Sciences de la santé humaine / Survival / Thrombocytopenia / Toxicity / Tumors / Young Adult

2016

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

2016

Confirm

Do you wish to request the book?

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

2016

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Ledermann, Jonathan A,

Mądry, Radosław,

Vergote, Ignace,

Agarwal, Shefali,

Buscema, Joseph,

Dørum, Anne,

Christensen, René D,

Follana, Philippe,

Oza, Amit M,

Redondo, Andrés,

Fabbro, Michel,

Berek, Jonathan S,

Marth, Christian,

Benigno, Benedict,

Lorusso, Domenica,

Herrstedt, Jørn,

Balser, John P,

Tinker, Anna V,

Gilbert, Lucy,

Monk, Bradley J,

González-Martín, Antonio,

Matulonis, Ursula A,

Rosenberg, Per,

Ben-Baruch, Noa E,

Mahner, Sven,

Mirza, Mansoor R,

du Bois, Andreas,

Rimel, Bobbie J

2016

Overview

Among patients with platinum-sensitive, recurrent ovarian cancer, the use of niraparib, a PARP inhibitor, was associated with a significantly longer duration of progression-free survival than placebo, with moderate bone marrow toxicity. Ovarian cancer is a leading cause of death from gynecologic cancers worldwide. 1 , 2 Despite a high initial response rate to platinum and taxane treatment in patients with advanced cancer, the effectiveness of the treatments diminishes over time, and most patients have a relapse. 3 Platinum retreatment is used in patients in whom there is an assumed platinum sensitivity, with diminishing effectiveness and a cumulative increase in toxicity. 3 Niraparib is a highly selective inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) 1/2, 4 nuclear proteins that detect DNA damage and promote its repair. Clinical studies have evaluated PARP inhibitors in patients with recurrent ovarian . . .

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adenosine

/ Adolescent

/ Adult

/ Aged

/ Aged, 80 and over

/ Antineoplastic Agents - adverse effects

/ Antineoplastic Agents - therapeutic use